Satellos Bioscience Inc.

Satellos Bioscience Inc. (NASDAQ:MSLE) is a publicly traded company in the Life Sciences sector. Wiseek monitors MSLE SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

• Satellos Reports Positive Six-Month Interim Data for SAT-3247 in Adult DMD Patients (2026-07-08)
• SAT-3247 Shows Positive Six-Month Data in DMD Adults, Reducing Muscle Fat and Improving Effort (2026-07-08)
• Satellos Bioscience Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Drug (2026-06-29)
• FDA Grants Fast Track to Satellos' SAT-3247 for Duchenne Muscular Dystrophy (2026-06-29)
• Satellos to Present New Clinical Data for SAT-3247 at ICNMD 2026 (2026-06-25)

Insider Transactions

MSLE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.